Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective...

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis C virus (HCV) infection is a global health concern.
• Mixed cryoglobulinaemia is a known complication of chronic HCV infection.
• The prevalence and predictive factors of HCV-associated mixed cryoglobulinaemia in Asia require further investigation.

Purpose of the Study:

• To determine the prevalence of mixed cryoglobulinaemia in Taiwanese individuals with chronic HCV infection.
• To identify factors associated with the development and persistence of mixed cryoglobulinaemia.
• To evaluate the impact of anti-HCV therapy and sustained virological response (SVR) on mixed cryoglobulinaemia.

Main Methods:

• An 8-year prospective cohort study involving 678 Taiwanese patients with chronic HCV infection.
• Assessment of mixed cryoglobulinaemia and mixed cryoglobulinaemic syndrome at baseline and post-therapy.
• Analysis of baseline and post-therapy IgM, IgG, rheumatoid factor (RF) levels, and HCV genotype.
• Evaluation of outcomes in patients achieving SVR versus non-SVR.

Main Results:

• Over 64% of patients had mixed cryoglobulinaemia, and 2.9% had mixed cryoglobulinaemic syndrome.
• Baseline IgM, triglycerides, IgG, and HCV genotype 3 were associated with mixed cryoglobulinaemia.
• RF levels predicted mixed cryoglobulinaemic syndrome.
• SVR was associated with higher rates of mixed cryoglobulinaemia cure and lower persistence.
• Pre-therapy IgM levels predicted new and persistent mixed cryoglobulinaemia in SVR patients.
• Long-term follow-up showed persistent mixed cryoglobulinaemia in a subset of SVR patients.

Conclusions:

• Mixed cryoglobulinaemia is highly prevalent in chronic HCV-infected individuals in Taiwan.
• Baseline immunological markers (IgM, RF) are crucial for identifying patients at risk.
• Achieving SVR significantly improves outcomes related to mixed cryoglobulinaemia.
• Long-term monitoring is essential for SVR patients, as mixed cryoglobulinaemia can persist.